University of Cincinnati, Center for Reproductive Health, Cincinnati, OH, USA.
Expert Opin Pharmacother. 2012 Sep;13(13):1937-42. doi: 10.1517/14656566.2012.705832. Epub 2012 Jul 7.
Emergency contraceptive agents play a crucial role in preventing unplanned pregnancy. These agents and devices have been studied since the 1960s and have had varied results in terms of side effects and efficacy. A new oral tablet for emergency contraception (EC), ulipristal acetate (UPA) , is a selective progesterone receptor modulator and can be used up to 120 h following unprotected intercourse, without an increase in adverse effects or a decrease in efficacy.
This article reviews studies that evaluate the pharmacodynamics, pharmacokinetics, clinical efficacy, and safety profile of UPA as an emergency contraceptive agent.
UPA, a selective progesterone receptor modulator, is administered as a single 30 mg dose for EC. This agent provides a comparable, if not better, efficacy and side effect profile than seen with levonorgestrel or mifepristone. Because it has both agonistic and antagonistic effects on the progesterone receptor, ongoing clinical trials are documenting UPA's use for patients with endometriosis and as an extended use contraceptive.
紧急避孕药物在预防意外怀孕方面发挥着重要作用。自 20 世纪 60 年代以来，人们一直在研究这些药物和器具，其在副作用和效果方面的结果各不相同。一种新的紧急避孕口服片剂（EC），醋酸乌利司他（UPA），是一种选择性孕激素受体调节剂，可在无保护性交后 120 小时内使用，而不会增加不良反应或降低疗效。
本文综述了评估 UPA 作为紧急避孕药物的药效学、药代动力学、临床疗效和安全性特征的研究。
UPA，一种选择性孕激素受体调节剂，作为 EC 单次给予 30mg 剂量。与左炔诺孕酮或米非司酮相比，该药物的疗效和副作用特征相似，甚至更好。由于它对孕激素受体既有激动作用，也有拮抗作用，正在进行的临床试验正在记录 UPA 在子宫内膜异位症患者中的使用情况，以及作为延长使用的避孕方法。
